TrialCompass™ TCL
Back to trials
RecruitingPriority 2 · High priorityNCT06810778

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

ClinicalTrials.gov

Plain-language summary

This trial is testing duvelisib (an oral PI3K inhibitor) for patients with cutaneous T-cell lymphoma (CTCL) or T-cell prolymphocytic leukemia whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

Who can join (key eligibility)

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Duvelisib (DRUG): 15 and 25 mg BID | Venetoclax (DRUG): 200, 400, and 800 mg QD

  • Duvelisib, Venetoclax

Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details

Learn more

What is CTCL?

Plain-language overview of CTCL plus all curated trials for this subtype.

Use our AI Assistant

Ask questions about this trial, eligibility, or T-cell lymphoma in general.

Generate a letter for your doctor

Create a printable letter to discuss this trial with your oncologist.

TrialCompass — Clinical Trial Summary

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT06810778

Phase: Phase 1, Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

This trial is testing duvelisib (an oral PI3K inhibitor) for patients with cutaneous T-cell lymphoma (CTCL) or T-cell prolymphocytic leukemia whose disease has come back or stopped responding to prior treatment. This is a Phase 1/2 trial, which means researchers are determining the best dose and getting early information about effectiveness. This trial is available at 1 location in the United States. The trial is currently recruiting patients.

Who can join

  • Age 18 Years or older
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

Duvelisib (DRUG): 15 and 25 mg BID | Venetoclax (DRUG): 200, 400, and 800 mg QD

Drugs / treatments: Duvelisib, Venetoclax

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 12 patients

Primary endpoint: Determine the dose limiting toxicities (DLTs), for the combination regimen of duvelisib plus venetoclax for patients with relapsed or refractory PTCL; Determine the Maximum Tolerated Dose MTD); Recommended phase II dose (Phase I)

Ages: 18 Years to —

Start date: 2025-05-02 | Est. completion: 2031-06-01

Locations

1 US sites · 1 total

California

Contact

Vladimir Bonhomme | VBonhomme@mednet.ucla.edu | 310-794-6500

Sponsor: Jonsson Comprehensive Cancer Center (OTHER)

Tags

CTCL · T-PLL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06810778

Prepared using TrialCompass (trialcompass.com) on August 3, 2026. For informational purposes only. Always discuss with your healthcare team.